FDA Accepts Bristol Myers Squibb’s Supplemental New Drug Application for CAMZYOS
Bristol Myers Squibb declared that the U.S. FDA had accepted its supplemental new drug application for CAMZYOS for an expanded indication to reduce the need for septal reduction therapy. CAMYZOS is currently FDA-approved for treating adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
"Currently, it is suggested that many patients suffering with severe symptomatic obstructive hypertrophic cardiomyopathy undergo septal reduction therapy. This often requires either an open-heart surg...
